311 related articles for article (PubMed ID: 35411506)
41. Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Nagaya Y; Nozaki Y; Kobayashi K; Takenaka O; Nakatani Y; Kusano K; Yoshimura T; Kusuhara H
Drug Metab Pharmacokinet; 2014; 29(5):419-26. PubMed ID: 24806821
[TBL] [Abstract][Full Text] [Related]
42. Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution.
Langthaler K; Jones CR; Saaby L; Bundgaard C; Brodin B
Fluids Barriers CNS; 2024 Jan; 21(1):11. PubMed ID: 38273301
[TBL] [Abstract][Full Text] [Related]
43. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
Uchida Y; Wakayama K; Ohtsuki S; Chiba M; Ohe T; Ishii Y; Terasaki T
J Pharmacol Exp Ther; 2014 Sep; 350(3):578-88. PubMed ID: 24947467
[TBL] [Abstract][Full Text] [Related]
44. QSAR Model of Unbound Brain-to-Plasma Partition Coefficient, K
Dolgikh E; Watson IA; Desai PV; Sawada GA; Morton S; Jones TM; Raub TJ
J Chem Inf Model; 2016 Nov; 56(11):2225-2233. PubMed ID: 27684523
[TBL] [Abstract][Full Text] [Related]
45. In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms.
Chen H; Winiwarter S; Fridén M; Antonsson M; Engkvist O
J Mol Graph Model; 2011 Aug; 29(8):985-95. PubMed ID: 21571561
[TBL] [Abstract][Full Text] [Related]
46. The brain slice method for studying drug distribution in the CNS.
Loryan I; Fridén M; Hammarlund-Udenaes M
Fluids Barriers CNS; 2013 Jan; 10(1):6. PubMed ID: 23336814
[TBL] [Abstract][Full Text] [Related]
47. Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?
Hammarlund-Udenaes M
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):215-20. PubMed ID: 20050843
[TBL] [Abstract][Full Text] [Related]
48.
Zhang W; Oh JH; Zhang W; Aldrich CC; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2024 Apr; ():. PubMed ID: 38670802
[TBL] [Abstract][Full Text] [Related]
49. CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice.
Campagne O; Davis A; Zhong B; Nair S; Haberman V; T Patel Y; Janke L; F Roussel M; Stewart C
J Pharm Pharm Sci; 2019; 22(1):612-629. PubMed ID: 31815662
[TBL] [Abstract][Full Text] [Related]
50. Insight into tissue unbound concentration: utility in drug discovery and development.
Mariappan TT; Mandlekar S; Marathe P
Curr Drug Metab; 2013 Mar; 14(3):324-40. PubMed ID: 23167621
[TBL] [Abstract][Full Text] [Related]
51. In Vivo Quantitative Understanding of PEGylated Liposome's Influence on Brain Delivery of Diphenhydramine.
Hu Y; Gaillard PJ; Rip J; de Lange ECM; Hammarlund-Udenaes M
Mol Pharm; 2018 Dec; 15(12):5493-5500. PubMed ID: 30376346
[TBL] [Abstract][Full Text] [Related]
52. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
53. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
Sadiq MW; Salehpour M; Forsgard N; Possnert G; Hammarlund-Udenaes M
Drug Metab Dispos; 2011 Feb; 39(2):174-9. PubMed ID: 21059857
[TBL] [Abstract][Full Text] [Related]
54. Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.
Samala R; Thorsheim HR; Goda S; Taskar K; Gril B; Steeg PS; Smith QR
Pharm Res; 2016 Dec; 33(12):2904-2919. PubMed ID: 27541873
[TBL] [Abstract][Full Text] [Related]
55. Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology.
Gustafsson S; Lindström V; Ingelsson M; Hammarlund-Udenaes M; Syvänen S
Neuropharmacology; 2018 Jan; 128():482-491. PubMed ID: 28797721
[TBL] [Abstract][Full Text] [Related]
56. Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu).
Gupta A; Chatelain P; Massingham R; Jonsson EN; Hammarlund-Udenaes M
Drug Metab Dispos; 2006 Feb; 34(2):318-23. PubMed ID: 16303872
[TBL] [Abstract][Full Text] [Related]
57. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of pericyte involvement in small-molecular drug transport across the blood-brain barrier.
Mihajlica N; Betsholtz C; Hammarlund-Udenaes M
Eur J Pharm Sci; 2018 Sep; 122():77-84. PubMed ID: 29933077
[TBL] [Abstract][Full Text] [Related]
59. Characterization of Aripiprazole Uptake Transporter in the Blood-Brain Barrier Model hCMEC/D3 Cells by Targeted siRNA Screening.
Kadoguchi M; Arakawa H; Honda R; Hotta K; Shirasaka Y; Deguchi Y; Tamai I
Pharm Res; 2022 Jul; 39(7):1549-1559. PubMed ID: 35314999
[TBL] [Abstract][Full Text] [Related]
60. Perspectives on Nanodelivery to the Brain: Prerequisites for Successful Brain Treatment.
Hu Y; Hammarlund-Udenaes M
Mol Pharm; 2020 Nov; 17(11):4029-4039. PubMed ID: 33064009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
